Single-cell multi-omics analysis identifies metabolism-linked epigenetic reprogramming as a driver of therapy-resistant medulloblastoma
2024
Understanding Therapy-Resistant Medulloblastoma
publication
Evidence: moderate
Author Information
Author(s): Vibhakar Rajeev, Veo Bethany, Wang Dong, DeSisto John, Pierce Angela
Hypothesis
Can single-cell multi-omics analysis reveal mechanisms of therapy resistance in medulloblastoma?
Conclusion
The study found that metabolic reprogramming linked to chromatin changes drives therapy resistance in medulloblastoma.
Supporting Evidence
- Medulloblastoma is the most prevalent malignant brain tumor in children.
- Group 3 tumors display high levels of MYC and metastasis rates.
- A persistent progenitor population supporting resistance to therapy was identified.
- Distinct chromatin landscapes are linked to altered transcription and metabolic reprogramming.
- IDH1 inhibition reverses resistance-mediated chromatin changes.
Takeaway
This study looked at how some brain tumors in kids don't respond to treatment and found that changes in their cells' metabolism might be the reason.
Methodology
Single nuclei multiome analysis of matched primary and recurrent tumors was performed.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website